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Alcoholism is one of the leading diseases affecting people’s health and immunity 
worldwide. Nearly 30 thousand people in the USA die from chronic liver damage. The 
liver is the central organ in the metabolism of alcohol. Alcohol is primarily a hepatotoxic 
agent. Hepatotoxicity of alcohol is clinically manifested by the development of alcoholic 
fatty liver, alcoholic hepatitis and alcoholic cirrhosis. It is characterized by appropriate 
symptomatology, depending on the degree of liver damage. Excessive use of alcohol for 
a long period of time, along with malnutrition, genetic and ethnic predisposition, leads to 
alcoholic cirrhosis and the development of its complications. Portal hypertension 
damages other organs and organ systems, causing hepatopulmonary syndrome, 
hepatorenal syndrome, hepatic encephalopathy, spontaneous bacterial peritonitis, etc.  
For these reasons, alcoholism reduction is given priority, as well as reduction of 
morbidity and mortality of people with alcoholic chronic liver damage. Therefore, early 
diagnosis of alcohol abuse is necessary, as well as timely diagnosis of different degrees 
of alcoholic liver damage. 
The diagnosis of chronic alcoholic liver damage is set on the basis of confirmed data 
of alcohol consumption; liver function test (serum markers aminotransferase, gamma-
glutamyl transferase, prothrombin time, serum bilirubin and albumin level); serum 
markers of liver fibrosis. Fibrosis markers are directly involved in sedimentation and 
dissolution of extracellular matrix, i.e. in the process of fibrogenesis and fibrinolysis of 
liver tissues. They include markers and enzymes of metabolism, as well as cytokines and 
chemokines. Acta Medica Medianae 2011;50(4):55-61. 
 
 Key  words:   alcoholic liver damage, serum marker 
 
University of Priština, Medical Faculty in Kosovska Mitrovica, 
Institute for Infective Deseases, Kosovska Mitrovica, Serbia
1 
University of Niš, Faculty of Medicine, Institute of Biochemistry, 
Niš, Serbia
2 
University in Niš , Institute of Pathophysiology, Faculty of 
Medicine, Niš, Serbia
3 
 
Contact: Vanja Ničković 
University of Pristina, Medical Faculty in Kosovska Mitrovica, 
Institute for Infective Deseases, Kosovska Mitrovica, Serbia  
E-mail: vanja.j@open.telekom.rs 
 
 
Introduction 
 
  Alcoholism is the third most common cause 
of death, after cardiovascular and oncologic 
diseases. According to epidemiological data, the 
number of alcoholics encompasses about 5% of 
people in general population, i.e. 10% of adult 
males. The largest number of alcoholics is in the 
most productive period of live, from thirty to the 
fifty years of age.   
  Chronic alcohol consumption causes liver 
damage. Nearly 30 thousand people die of 
chronic liver damage every year in the USA (1, 
2). Liver damage may appear in the form of 
alcoholic fatty infiltration, alcoholic hepatitis and 
alcoholic cirrhosis. Alcoholic fatty liver and alcoholic 
hepatitis are reversible changes after cessation of 
alcohol use, whereas alcoholic cirrhosis is an 
irreversible liver damage. The degree of liver 
damage depends on the dose, or alcohol concen-
tration, as well as the length of alcohol use. Liver 
damage depends on gender and ethnicity, genetic 
predisposition and nutrition (3, 4).  
  Fatty liver develops in about 20% of severe 
alcoholics. In many cases there are no clinical 
symptoms, except liver enlargement (hepato-
megaly). In more than 60% of cases there are no 
predispositions for serious liver damage if a 
person abstains from alcohol use.  
  Alcoholic hepatitis develops with long and 
continuous alcohol use. Clinical signs of alcoholic 
hepatitis include: liver enlargement, nausea, 
vomiting, jaundice and stomach ache. In abstinence, 
it represents an acute form of liver damage. In 
biochemical terms, in about 10-30% of cases, it 
encompasses a spectrum of asymptomatic dis-
orders. If excessive alcohol use is continued, 
hepatitis will develop into cirrhosis in about 40% 
of cases. Mortality in severe liver damage is 
about 50% (5-7).  
  Alcoholic cirrhosis of the liver represents a 
terminal condition of a serious liver damage. It is 
present in 15-20% of case of alcoholic liver 
damage. Liver cirrhosis is characterized by diffuse 
fibrosis of the liver connective tissue, which 
causes deterioration of its structure, degene-
ration and destruction of hepatocytes. Liver Complications of alcoholic liver disease and diagnostic markers                                                                      Vanja Ničković et al. 
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cirrhosis is also characterized by inflammation 
process, associated with the release of cytokines 
and inflammation mediators, as well as the 
activation of lymphocytes and macrophages. 
They stimulate the creation of fibroblasts and 
connective-collagenous tissue. It is a progressive 
disease which leads to many complications 
associated with other organs and systems. The 
final complication of liver cirrhosis is portal 
hypertension. It is characterized by increased 
pressure in the liver sinuses, development of 
varices in the esophagus and stomach, spleno-
megaly, spider angioma, abdominal collateral 
veins and liquid buildup in peritoneal cavity (8). 
Portal hypertension further causes disorders in 
arteriovenous circulation in the lungs, hypoxemia, 
i.e. hepatopulmonary syndrome with the develop-
ment of cyanosis. Hepatic encephalopathy is a 
disorder of the brain function, which develops 
because the liver is unable to remove toxic 
materials, such as ammonia from the blood.  
  Hepatorenal syndrome is a disorder in the 
function of the kidneys. It is characterized by 
reduced renal circulation, retention of sodium and 
water, as well as the development of azotemia. 
Spontaneous bacterial peritonitis is the most 
significant complication of cirrhosis with ascites. 
It is characterized by fever, abdominal pain and 
leukocytosis. Hematologic disorders in cirrhosis 
include leukopenia, thrombocytopenia, anemia, 
coagulopathy and hemosiderosis. Endocrine compli-
cations in liver cirrhosis include gynecomastia, 
testicular atrophy, feminism, sexual impotence in 
men, whereas infertility and amenorrhea develop 
in women (9-13). 
  Hepatocellular liver carcinoma is a serious, 
late complication of chronic liver disease. In the 
majority of cases it develops in alcoholic liver 
cirrhosis. Hepatocellular carcinoma develops in 
10-15% of patients with alcoholic cirrhosis.  It is 
the fifth most frequent malignant disease in the 
world. In about 90% of cases, in patients with 
cirrhosis who stop drinking, survival is around 5 
years, whereas in 70% of cases, in patients who 
do not stop drinking, survival is less than 5 
years. In patients with cirrhosis and developed 
ascites, the survival rate is higher if they stop 
drinking, compared to patients who do not stop 
drinking (14).  
 
  General diagnostic markers 
 
  The diagnosis of chronic alcoholic liver 
damage is established by noninvasive and invasive 
methods. Synthetic liver function test is a non-
invasive method. This test includes the determi-
nation of serum marker activity (transaminases, 
glutamyltranserases, concentration of albumin and 
total protein) and determination of serum 
bilirubin and prothrombin time. SVS test can 
confirm the symptoms of liver damage as well as 
anemia. It is assumed that alcohol is the cause of 
liver damage in patients whose alcohol consumption 
is chronic and excessive. The dose for men is 
more than 60 g a day, while for women it is 40 g 
a day. 
  Aminotransaminases. In the serum of healthy 
people the AST/ALT ratio is less than 1. In liver 
parencyma damage caused by alcohol, trans-
aminases activity in serum is moderately 
increased. In alcoholic hepatitis the AST/ALT ratio 
is higher than 2 because Alt activity is reduced. 
AST is a specific marker of alcoholic liver damage 
and an increase in its activity is more persistent 
in serum. However, in the progression of chronic 
hepatitis with significant hepatocyte necrosis, ALT 
activity is increased by 5-6 times. AST activity 
increases by 10-20 times above normal (15).  
  Gamma glutamyl transferase (γ-GT) is the 
most important enzyme in the diagnosis of 
alcoholic liver damage. A quick increase of γ-GT 
in serum is characteristic in alcoholics with 
alcoholic hepatitis in acute stage of liver damage. 
In this stage, increase in ALT and glutamate 
dehydrogenase is slower.  
  In the early stage of liver damage, the 
increase in γ-GT in serum is the only sign of liver 
damage. Activity of γ-GT is higher due to 
increased metabolism of ethanol which is done by 
this enzyme, as well as because of cholestasis 
which develops as a consequence of taking other 
narcotics or medicines.   
  In chronic alcohol consumers who do not 
have serious liver damage, the values of γ-GT in 
serum are 2 to 3 times higher. However, in 
chronic alcohol consumers with liver damage the 
values of γ-GT in serum are 10 to 20 times 
higher (16). 
  Serum albumin can be low, which is usually 
a consequence of malnutrition or liver damage 
with reduced albumin synthesis function.  
  Prothrombin time (PT) is lengthened in 
severe liver damage. The reason for this is a 
coagulation disorder developed due to reduced 
synthesis of coagulation factors, reduced number 
of thrombocytes and vitamin K deficit. Reduced 
number of thrombocytes is caused by hyper-
splenism, whereas vitamin K deficit is a conse-
quence of cholestasis, digestion disorders and 
liposoluble vitamin absorption.  
  Serum bilirubin is an indicator of secretory 
liver function. In the beginning of the disease, at 
low degree of damage, conjugated bilirubin is 
dominant in serum.  
  Macrocytosis with MCV above 100 is a 
consequence of direct effects of alcohol on the 
bone marrow. Malnutrition, which leads to folate 
deficiency, is also a cause of macrocytic anemia. 
Thrombocytopenia can be a consequence of 
either direct toxic effect of alcohol on the bone 
marrow or splenomegaly. Neutrophile lukocytosis 
can be present in alcoholic hepatitis and can be 
an indicator of an infection, primarily of severe 
pneumonia or severe peritonitis (17, 18).  
 
  Diagnostic markers of fibrosis 
 
  Alcoholic liver cirrhosis is characterized by 
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fatty liver and alcoholic hepatitis, as well as the 
appearance of specific markers of fibrosis. Fibrosis 
is an unspecific response to damage which 
includes synthesis of extracellular matrix (ECM). 
ECM represents a group of macro-molecules, 
collagenous and non-collagenous glyco-proteins, 
growth factor of matrix, glycosamino-glycans, 
proteoglycans and matrix proteins (19). During 
the process of fibrinogenesis, both quantitative 
and qualitative changes take place. Total collagen 
content in the liver increases 3-10 times. 
Qualitative changes include increase in filament-
forming collagen (type I, III and IV), non-
filament-forming collagen (type IV and VI), 
glycoproteins (fibronectin, laminin, osteonectin, 
tenascin, von Willebrand factor), protoglycans 
and glycosaminoglycans (perlecan, decorin, aggre-
can, lumican and fibromodulin).  
  The result is the replacement of low-density 
matrix by high-density matrix of interstitial type. 
Metabolism, synthesis and function of hepatocytes, 
and stellate and endothelial cells are disturbed in 
the liver parenchyma.  
  The central leading event in liver pathology 
is the activation of liver stellate liver cells which 
leads to liver fibrosis. 
  Activation of stellate cells includes two steps; 
initiation of ‘preinflammatory phase’ and changes 
such as proliferation, chemotaxis, fibrogenesis, 
contractility, matrix degradation, loss of retinoid 
and release of WBC chemokines and cytokines. 
Fibrosis markers are directly included in sedi-
mentation and dissolution of ECM, i.e.in the 
process of liver fibrogenesis and fibrolysis (20, 21).  
  They include the markers and enzymes of 
the metabolism of matrix sedimentation and 
dissolution, proliferation of connective tissue, as 
well as cytokines and chemokines. Every phase 
of liver fibrosis demands the presence of specific 
cytokines, chemokines or other biologically active 
mediators. Fibrosis markers can be classified 
according to their molecular structure. These are 
mostly the components of fibrous tissue, various 
types of collages and their precursors, fibrillary 
proteins, and enzymes included in the dissolution 
of connective tissue (22-26). Fibrosis markers 
are divided into: sedimentation markers in the 
matrix, matrix dissolution markers and cytokines 
with chemokines (Table 1). 
 
  Markers of disposal in the matrix 
 
Collagen I is a fibril-forming type of collagen 
which develops by post-translation modification of 
procollagen I. During collagen synthesis, under the 
effect of procollagen C and N proteinase enzyme, 
procollagen undergoes enzymatic changes at 
carboxyl and amino terminal ends. Peptides are 
released I serum as procollagen type I carboxyl-
terminal peptide and procollagen type III amino-
terminal peptide. They are used as a measure of 
sedimentation in the matrix (26). 
Procollagen type I carboxyl-terminal peptide 
(P I CP) is a fragment obtained by procollagen I 
breakdown by the effect of peptidase before 
secretion from fibrocytes. For this reason, the 
determination of C-terminal peptide procollagen I 
can be used as a measure of disposal of collagen I. 
Collagen I with collagen III is the major component 
of total collagen in fibrous liver. Collagen types I 
and III are broken down proteolytically. Procollagen 
type I carboxyl-terminal peptide is significantly 
increased in cirrhosis and points to liver damage 
of alcoholic etiology (27). 
Procollagen type III amino-terminal peptide 
(P III NP). Procollagen III is synthesized in firo-
blasts as biosynthetic precursor of collagen III. 
N-terminal peptide is obtained at the conversion 
of procollagen III into collagen III in extracellular 
space. There is a correlation between the level of 
this marker and the degree of liver fibrosis in 
alcoholic liver damage, viral hepatitis and 
primary biliary cirrhosis (28). 
Collagen IV is the major component of basal 
membranes. It appears in the form of tetramer 
aggregates. Compared to collagen type I and III 
which are porteolytically processed, collagen type 
IV is deposited intact in the extracellular matrix. 
Type IV collagen maintains the condition of 
extracellular matrix. It increases 14 times during 
fibrogenesis in the liver. It is most often used in 
practice.  
Type IV collagen in serum is in a positive 
correlation with the degree of liver fibrosis in 
patients with chronic viral hepatitis and alcoholic 
liver damage. It is a sensitive indicator of the 
presence of hemochromatosis in alcoholic cirrhosis. 
Values above 110 ng/ml indicate phase F2, while 
values above 130 ng/ml indicate phase F3 cirrhosis 
(29, 30). 
Table 1.  Markers of fibrosis 
 
Collagens   Procollagen type I , III и IV, Type IV collagen  
Markers of disposal in 
the matrix  Glycoproteins  and 
Glycosaminoglycans 
Laminin and Hyaluronic acid  
Enzymes 
collagenpeptidase, prolilhydroxylase, 
monoamineoxidase, lizilhydroxylase  Matrix dissolution 
markers  Matrix-metaloproteinase  and their 
inhibitors  
ММP-2 , ТIМP-1, ТIМP-2, сICАМ-1, сVCАМ-1 
… 
Transforming growth factor-β1   ТGF-β1  Cytokines and 
chemokines of liver 
fibrosis   Platelet growth factor   PGF 
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Prolyl hydroxylase catalyses the process of 
hydroxylation of prolyl remains in procollagen 
into hydroxyprolyl. The deficit in vitamin E and 
selenium with increase in aminoterminal pro-
collagen III peptide points to active hepatic 
fibrosis. 
Laminin. One of the major glycoproteins of 
basal membrane is laminin which is synthesized 
in hepatocytes and sinusoid cells. Laminin 
increases during fibrosis because of increased 
synthesis of laminin in the liver and lack of its 
degradation by endothelial liver cells. During 
fibrosis, it accumulates around blood vessels 
perisinusoidally and around portal tract. 
It is in correlation with the progression of 
liver fibrosis and the degree of inflammation in 
chronic hepatitis. It is also correlated with serum 
level of ALT which reflects the degree of liver 
damage, especially in cirrhosis. It is superior in 
reflecting the degree of liver damage than serum 
level of ALT. Serum level of laminin reflects the 
gradient of portal pressure in the liver, as well as 
in vena porta (31, 32). It has been suggested 
that the measurement of laminin concentration in 
serum be a sensitive test for determining the 
degree of liver damage, as well as the degree of 
portal hypertension development. 
Hyaluronic acid (HA) is glycosaminoglycan, 
a component of ECM, which is synthesized in 
hepatocytes. In normal circumstances, endothelial 
cells of liver sinusoids synthesize and degrade 
the hyaluronic acid. The high level of serum HA 
has been discovered in patients with liver disease 
of various etiologies. It is significantly higher in 
patients with cirrhosis. When serum level of HA is 
below 60 mg/l, serious liver cirrhosis is excluded, 
as well as serious vein fibrosis. Early fibrosis is 
identified. When serum level is around 85 mg/l of 
serum, HA has the sensitivity of 64.5% for the 
development of severe liver fibrosis. When the 
values are around 110 mg/l, HA has the sensitivity 
of 79.2% for the development of severe liver 
fibrosis (33, 34). The determination of the level 
of laminin and HA has prognostic significance in 
the complication of liver cirrhosis, such as hepatic 
encephalopathy, ascites and portal venous 
thrombosis. 
 
Matrix dissolution markers 
 
Extracellular matrix is an active tissue 
where a dynamic process takes place, such as 
synthesis and dissolution of matrix. This leads to 
ECM remodulation. It is very difficult to make a 
clear distinction between sedimentation markers 
and dissolution markers of ECM. In serum, these 
markers reflect both processes simultaneously, 
and the total mass of ECM goes through the 
process of adaptation (35). 
The products of matrix dissolution are a 
result of activity of a family of matrix metalo-
proteinase (MMPs) enzymes. Synthesized intra-
cellularly, they are secreted as MMPs pro-
enzymes. They are activated by proteolytic effect 
of membrane type 1 matrix metaloproteinase 
( M T 1 - M M P )  o r  b y  t h e  e f f e c t  o f  p l a s m i n ,  a n d  
inhibited by bonding to specific tissue inhibitors 
(TIMPs).  
Considering the specificity by substrate, 
there are five categories of MMPs: interstitial 
collagenase (MMP-1, 8, 13), gelatinase (MMP-2, 9 
and proteins of fibroblast activation), stromelysin 
(MMP-3, 7, 10, 11), membrane type (MMP-14, 
15, 16, 17, 24, 25) and metalloelastase (MMP-
12). MMPs and their inhibitors are included in the 
control of matrix degradation. 
The research of chronic liver disease is 
directed at MMP-2 and metalloproteinase mem-
brane type 1 or 2, which activate latent MMP-2, 
TIMP-1 and TIMP-2 (36). MMP-1 shows specificity 
for interstitial collagen type I and III substrate, 
while MMP-2 shows specificity for collagen type 
IV, V, VII, X, elastin and fibronectin substrate.  
TIMPs may irreversibly bond with proenzyme 
or active forms of MMPs and inactivate them. An 
excess of synthesized TIMPs in relation to MMPs 
can be an important factor in liver fibrosis pro-
gression. Stellate liver cells are a major source of 
MMP-2 in the human liver. The activation of MMP-
2 requires hepatocyte reaction. TIMP-1 are also 
produced by stellate cells and hepatocytes (37, 38). 
One study has shown that the level of 
MMP-2 is increased only in developed cirrhosis, 
while TIMP-1 has diagnostic significance in 
discovering an early phase of fibrosis. Serum 
level of TIMP-1 can also be significant in 
estimating liver fibrosis which is associated with 
active inflammatory activities. This study has 
shown that TIMP-1 level has a strong correlation 
with the inflammatory process, and that MP-2 
level is not connected with the phase of fibrosis 
in non-cirrhotic liver (39). Other studies have 
demonstrated that the level og serum MMP-1 
decreases with the degree of liver fibrosis and 
inflammation. High level of MMP-1 in serum is 
present in patients with late phase of fibrosis. 
The ratio between TMP-1 and MMP-1 can be 
useful in the diagnosis of liver fibrosis (39).  
 
Cytokines and chemokines of liver 
fibrosis  
 
Transforming growth factor-β1 (TGF-β1) is 
a homodimetric polypeptide which is secreted as 
inactive form that demands activation. It has a 
pleiotropic effect on the receptors of membranes 
of wide spectrum of cells. In liver pathology, 
TGF-β1 is the most important stimulant of ECM 
synthesis by stellate cells and it is also an 
inhibitor of growth and hepatocyte proliferation. 
In liver biopsy of patients with chronic liver 
damage, TGF-β1 and RNA levels are in correlation 
with messenger RNA of type I collagen (40, 41). 
There are limitations of TGF-β1 serum level 
because TGF-β1 bonds with location of damaged 
ECM and damaged vascular endothelium. The 
limitations are associated with seizure by soluble 
proteins and complication in TGF-β1 sample 
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These factors explain why plasma level of 
TGF-β1 has diagnostic significance. Some studies 
have shown a good correlation between total 
level of TGF-β1 in serum and the degree of 
fibrosis progression. Some authors give pro-
gnostic value to the border value of TGF-β1 level 
in patients without fibrosis progression, com-
pared to those in whom the disease has 
progressed. The level of TGF-β1 below 75 ng/ml 
points to a stable course of the disease (42, 43). 
Platelet growth factor (PGF) is the major 
stimulant in the proliferation and migration of 
stellate cells after liver damage. PGF-BB is the 
main subunit with the most important role in 
path signalization to stellate cells. One study has 
shown that serum level of PGF-BB has the 
highest significance in the assessment of liver 
fibrosis (44). 
It can be concluded that the analysis of 
serum biomarkers can assess the risk of health 
problems in alcoholics. Biomarker analysis 
contributes to understanding disease pathogenesis 
caused by alcohol, monitoring the natural 
development of the disease, as well as the 
diagnosis and disease prognosis. Thereby, both 
treatment and outcome can be improved. 
Simultaneous use of combination of sedimentation 
and ECM dissolution markers improves the 
accuracy in diagnosing the degree of fibrosis 
development. In this way, the process of 
remodeling and adaption o f  m a t r i x  c a n  b e  
estimated. Determination of serum markers is 
performed in order to control the intake of 
alcohol which should influence the reduction of 
alcoholic liver damage.  
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KOMPLIKACIJE ALKOHOLNE BOLESTI JETRE I DIJAGNOSTIČKI MARKERI 
  
Vanja Ničković, Jelenka Nikolić, Gordana Kocić, Milena Ilić i Boris Đinđić 
 
 
Alkoholizam predstavlja jednu od vodećih bolesti u većini zemalja u svetu. Od 
hroničnog oštećenja jetre u SAD svake godine umre blizu 30 hiljada ljudi. Jetra je 
centralni organ metabolizma alkohola. Alkohol je primarno hepatotoksični agens. Klinički 
se hepatotoksičnost alkohola manifestuje pojavom alkoholne masne jetre, alkoholnim 
hepatitisom i alkoholnom cirozom. Karakteriše se odgovarajućom simptomatologijom, 
zavisno od stepena oštećenja jetre. Prekomerno konzumiranje alkohola u dužem 
vremenskom periodu, pored malnutricije, genske i etničke predispozicije dovodi do 
alkoholne ciroze i razvoja njenih komlikacija. Portalna hipertenzija dovodi do oštećenja i 
drugih organa i sistema organa, kao što su hepatopulmonalni sindrom, hepatorenalni 
sindrom, hepatična encefalopatija, spontani bakterijski peritonitis i dr. 
Iz tog razloga prioritet se daje smanjenju alkoholizma, kao i smanjenju morbiditeta 
i mortaliteta obolelih od alkoholnog hroničnog oštećenja jetre. Zato je potrebno rano 
postavljanje dijagnoze zloupotrebe alkohola, kao i pravovremena dijagnoza različitog 
stepena alkoholnog oštećenja jetre.  
Dijagnoza hroničnog alkoholnog oštećenja jetre postavlja se na osnovu potvrđenog 
podatka o konzumiranju alkohola; testa funkcije jetre (serumski markeri aminotransfe-
raza, gama glutamil transferaza, protrombinsko vreme, serumski bilirubin i nivo 
albumina); serumskih markera fibroze jetre. Markeri fibroze su direktno uključeni u 
taloženje i razlaganje ekstracelularnog matriksa, odnosno u proces fibrogeneze i fibrolize 
tkiva jetre. Oni uključuju markere i enzime metabolizma, kao i citokine i hemokine.  Acta 
Medica Medianae 2011;50(4):55-61. 
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